Rituximab (R) Clinical Trials
7 recruitingDrug
Phase 24Phase 32Phase 12
Showing 1–7 of 7 trials
Recruiting
Phase 2
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.
Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07410520
Recruiting
Phase 3
Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
Granulomatosis With PolyangiitisMicroscopic Polyangiitis (MPA)
Ottawa Hospital Research Institute36 enrolled2 locationsNCT06983821
Recruiting
Phase 3
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation260 enrolled48 locationsNCT06006117
Recruiting
Phase 2
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Mantle Cell Lymphoma (MCL)
Ruijin Hospital25 enrolled1 locationNCT07272499
Recruiting
Phase 2
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
Mantle Cell Lymphoma (MCL)
Ruijin Hospital45 enrolled1 locationNCT07199296
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Mature B-cell Malignancies
InnoCare Pharma Inc.78 enrolled8 locationsNCT06351527
Recruiting
Phase 1Phase 2
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China108 enrolled1 locationNCT06594640